IDXX Stock Recent News

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, alon.

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX websi.

The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion.

Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on.

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.